In our study, we deployed a customized targeted panel (Archer® LiquidPlexTM) comprising 29 cancer and/or GIST-associated genes, emphasizing the utility of a larger sequencing footprint in picking up clinically relevant mutations beyond KIT and PDGFRA. Similar to a previous report (18), the sensitivity of our assay depends on tumor size, and is most applicable in the setting of progressive disease and TKI resistance. This evidence concerns the gene PDGFRA and gastrointestinal stromal tumor.